ABVC BioPharma (ABVC) S-1/A 14 Nov 16 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	American BriVision (Holding) Corp
Entity Central Index Key	1,173,313
Document Type	S-1/A
Trading Symbol	ABVC
Document Period End Date	Jun. 30, 2016
Amendment Flag	true
Amendment Description	CALCULATION OF REGISTRATION FEE Title of each class of securities to be Amount to Proposed Proposed Amount of Common stock, par value $.001 per share offered by certain selling stockholders 32,409,505 (3) $ 2.00 $ 64,819,010 $ 6,528 Total 32,409,505 $ 64,819,010 $ 6,528 (1) Pursuant to Rule 416 of the Securities Act of 1933, also registered hereby are such additional and indeterminable number of shares as may be issuable due to adjustments for changes resulting from stock dividends, stock splits and similar changes. (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, based on the average of the high and low sales price of the common stock on the OTCQB Market on August 24, 2016. (3) The 32,409,505 shares of common stock are being registered for resale by certain selling stockholders named in this registration statement, which shares were issued by the registrant in the Share Exchange, as defined below. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a) may determine.
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Current assets
Cash	$ 84,904	$ 994,830
Prepayment	3,500,000	3,815
Total Current Assets	3,584,904	998,645
Non-current assets
Deposit	3,815	3,815
Total Assets	3,588,719	1,002,460
Liabilities and Equity
Accounts Payable	11,446
Other payable		300,000
Due to related party		22,517
Due to shareholder		46,586
Short term loan	2,050,000
Total Liabilities	2,061,446	369,103
Commitments and Contingencies
Stockholders'equity
Common Stock	209,353	166,274
Additional paid-in capital	1,987,127	1,132,685
Subscription receivable		(350,000)
Accumulated deficit	(669,207)	(315,602)
Total equity	1,527,273	633,357
Total liabilities and equity	$ 3,588,719	1,002,460
Metu Brands, Inc [Member]
Current assets
Cash		994,830
Prepayment		3,815
Total Current Assets		998,645
Non-current assets
Deposit		3,815
Total Non-Current Assets		3,815
Total Assets		1,002,460
Liabilities and Equity
Other payable		300,000
Due to related party		22,517
Due to shareholder		46,586
Total Liabilities		369,103
Commitments and Contingencies
Stockholders'equity
Common Stock		166,274
Additional paid-in capital		1,132,685
Subscription receivable		(350,000)
Accumulated deficit		(315,602)
Total equity		633,357
Total liabilities and equity		$ 1,002,460

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2016	Mar. 21, 2016	Sep. 30, 2015
Statement of Financial Position [Abstract]
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common Stock, authorized	360,000,000	360,000,000	360,000,000
Common Stock, issued	209,352,897		166,273,921
Common Stock, outstanding	209,352,897		166,273,921

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	2 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2016
Revenues
Cost of sales			32
Gross profit loss			(32)
Operating expenses
Selling, general and administrative expenses	315,602	289,098	349,486
Net income (loss) from operations	(315,602)	(289,098)	(349,518)
Other income (expense)
Bank Interest Income		361	361
Gain on exchange differences		89	141
Interest Expense		(3,753)	(3,753)
Total Other Income (Expense)		(3,303)	(3,251)
Income (loss) from continuing operations before income taxes	(315,602)	(292,401)	(352,769)
Income taxes		(836)	(836)
Net income (loss)	$ (315,602)	$ (293,237)	$ (353,605)
Basic and Diluted loss per share
Basic and Diluted income (loss) per share (in dollars per share)	$ 0	$ 0	$ 0
Weighted average number of shares outstanding basic and diluted (in shares)	160,823,831	208,845,898	188,626,862
Metu Brands, Inc [Member]
Operating expenses
Selling, general and administrative expenses	$ 315,602
Net income (loss) from operations	(315,602)
Other income (expense)
Income (loss) from continuing operations before income taxes	(315,602)
Net income (loss)	$ (315,602)
Basic and Diluted loss per share
Basic and Diluted income (loss) per share (in dollars per share)	$ 0
Weighted average number of shares outstanding basic and diluted (in shares)	160,823,831

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Metu Brands, Inc [Member]	Total
Balance at beginning at Sep. 30, 2013	$ 11	$ 1	$ 28,670,072	$ (30,550,258)		$ (1,880,174)
Balance at beginning (in shares) at Sep. 30, 2013	11,144	271
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income					$ (23,235)
Balance at ending at Sep. 30, 2014	$ 11	$ 1	54,582	(23,235)		31,359
Balance at ending (in shares) at Sep. 30, 2014	11,144	271
Balance at beginning at Sep. 30, 2013	$ 11	$ 1	28,670,072	(30,550,258)		(1,880,174)
Balance at beginning (in shares) at Sep. 30, 2013	11,144	271
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Fresh start adjustments			(30,495,734)	30,550,328		54,594
Reorganization adjustments			1,880,244			(1,880,244)
Net income				(70)		(70)
Balance at ending at Sep. 18, 2014	$ 11	$ 1	54,582			54,594
Balance at ending (in shares) at Sep. 18, 2014	11,144	271
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income				(23,235)		(23,235)
Balance at ending at Sep. 30, 2014	$ 11	$ 1	54,582	(23,235)		31,359
Balance at ending (in shares) at Sep. 30, 2014	11,144	271
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued as compensation	$ 30,000					30,000
Stock issued as compensation (in shares)	30,000,000
Bankruptcy shares issued	$ 30,000		(30,000)
Bankruptcy shares issued (in shares)	30,000,000
Net income				(32,281)	(32,281)	(32,281)
Balance at ending at Sep. 30, 2015	$ 60,011	$ 1	$ 24,582	$ (55,516)	$ 633,357	633,357
Balance at ending (in shares) at Sep. 30, 2015	60,011,144	271
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income						(353,605)
Balance at ending at Jun. 30, 2016						$ 1,527,273

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) - USD ($)	2 Months Ended	9 Months Ended
	Sep. 30, 2015	Jun. 30, 2016
Cash flows from operating activities
Net income (loss) from continuing operations	$ (315,602)	$ (353,605)
Adjustments to reconcile net loss to net cash used by operating activities:
(Increase) decrease in deposit	(3,815)
(Increase) decrease in prepayment	(3,815)	(2,596,185)
(Increase) decrease in due from related party		350,000
Increase (decrease) in other payable	300,000	(300,000)
Increase (decrease) in due to related party	22,517	(22,517)
Increase (decrease) in due to shareholder	46,586	(46,586)
Increase (decrease) in accounts payable		11,446
Net cash used in operating activities	45,871	(2,959,926)
Cash flows from investing activities
Net cash provided (used) by investing activities
Cash flows from financing activities
Proceeds from short term loans		2,050,000
Proceeds from issuance of shares	948,959
Net cash provided(used) by financing activities	948,959	2,050,000
Effect Of Exchange Rates On Cash
Net increase(decrease) in cash	994,830	(909,926)
Cash, beginning of period		994,830
Cash, end of period	994,830	84,904
Non cash investing and financing activities
Prepayment		900,000
Supplemental disclosure of non-cash activities:
Interest paid
Income taxes paid
Metu Brands, Inc [Member]
Cash flows from operating activities
Net income (loss) from continuing operations	(315,602)
Adjustments to reconcile net loss to net cash used by operating activities:
(Increase) decrease in deposit	(3,815)
(Increase) decrease in prepayment	(3,815)
Increase (decrease) in other payable	300,000
Increase (decrease) in due to related party	22,517
Increase (decrease) in due to shareholder	46,586
Net cash used in operating activities	45,871
Cash flows from financing activities
Proceeds from issuance of shares	948,959
Net cash provided(used) by financing activities	948,959
Effect Of Exchange Rates On Cash
Net increase(decrease) in cash	994,830
Cash, beginning of period		$ 994,830
Cash, end of period	$ 994,830

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	9 Months Ended
	Jun. 30, 2016
ORGANIZATION AND DESCRIPTION OF BUSINESS	1. ORGANIZATION AND DESCRIPTION OF BUSINESS American BriVision (Holding) Corporation (the "Company" or "Holding entity"), a Nevada corporation, thru the Company's operating entity, American BriVision Corporation ("BriVision"), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center ("MSKCC") and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept ("POC"), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015. REVERSE MERGER On February 8, 2016, a Share Exchange Agreement ("Share Exchange Agreement") was entered into by and among American BriVision (Holding) Corporation (the "Company"), American BriVision Corporation ("BriVision"), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China ("Euro-Asia"), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of the Company(the "BriVision Stock"). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the "Acquisition Stock") (subject to adjustment for fractionalized shares as set forth below) of the Company's common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company's common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision's common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) shares of Company's common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company's common stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company's common stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the "Share Exchange"), BriVision became a wholly owned subsidiary (the "Subsidiary") of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. Because of the consummation of the Share Exchange, BriVision is now our wholly owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock. Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision's historical businesses and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept ("POC"), out-license to international pharmaceutical companies, and exploit global markets. For financial reporting purposes, the Share Exchange represents a "reverse merger" rather than a business combination and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company or acquiree. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Jun. 30, 2016	Sep. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting. Consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company's financial statements are expressed in U.S. dollars. The condensed financial statements include all adjustments that, in the opinion of management, are necessary in order not to make the financial statements misleading. Certain information and footnote disclosure normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. The results of operations for the periods ended June 30, 2016 are not necessarily indicative of the operating results for the full year. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results. Forward Stock split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation. See Note 7 for more details. Fair Value Measurements The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: • • • There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of September 30, 2015. Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of June 30, 2016, the Company's cash and cash equivalents amounted $84,904. As of September 30, 2015, the Company's cash and cash equivalents amounted $994,830. All of the Company's cash deposits are held in a financial institution located in Republic of China where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality. The Company owns no legal entities in PRC. Income Taxes The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. As of June 30, 2016 and September 30, 2015, the Company’s income tax expense amounted $836 and $0, respectively. Recent Accounting Pronouncements From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.
Metu Brands, Inc [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES		Note 1 — Summary of Significant Accounting Policies Description of the Company. Reclassifications. Basis of Preparation. Principles of Consolidation. Use of Estimates. Revenue Recognition. Loss Per Share. Property and Equipment. Computer equipment 3-10 years Furniture and fixtures 3-7 years Test equipment 5-7 years Signs 7 years Software 3 years Marketing and Promotional Video 3 years Repairs and maintenance costs are charged to operations as incurred. Betterments or renewals are capitalized as incurred. Patents. Long-Lived Assets. Stock-Based Compensation. We account for stock options granted to non-employees under the fair-value method with stock-based compensation expense being charged to earnings on the earlier of the date services are performed or a performance commitment exists. Recent Accounting Pronouncements We have reviewed all Accounting Standards Updates issued by the Financial Accounting Standards Board since we last issued financial statements and have determined none of them would have a material effect on the consolidated financial statements upon adoption.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Jun. 30, 2016
GOING CONCERN	Note 9 – Going Concern The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $669,207 as of June 30, 2016. The Company also incurred net losses of $353,605 and negative cash flow of $994,830 during the nine months ended September 30, 2016. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These combined financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company expects to finance operations primarily through cash flow from revenue and capital contributions from principal shareholders. In the event that we require additional funding to finance the growth of the Company's current and expected future operations as well as to achieve our strategic objectives, our principal shareholders have indicated the intent and ability to provide additional equity financing. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on our ability to meet obligations as they become due and to obtain additional equity or alternative financing required to fund operations until sufficient sources of recurring revenues can be generated. There can be no assurance that the Company will be successful in its plans described above or in attracting equity or alternative financing on acceptable terms, or if at all. The financial statements do not include any adjustments that might result from the outcome of this- uncertainty.

COLLAOBRATIVE AGREEMENT

COLLAOBRATIVE AGREEMENT	9 Months Ended
	Jun. 30, 2016
Collaobrative Agreement
COLLAOBRATIVE AGREEMENT	4 . COLLAOBRATIVE AGREEMENT On December 29, 2015, American BriVision Corporation entered into a Collaborative Agreement with BioLite Inc., a related party, pursuant to which BioLite granted the Company sole licensing rights for drug and therapeutic use of five products: BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in USA and Canada. The total consideration of obtaining such grant would be $100,000,000. Pursuant to the Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6 , 2016, we and Biolite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. This Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term. The Company determined to record the intangible assets and begin to amortize once the first commercial sales was consummated. The process related to first commercial sales has not begun as of June 30, 2016. The Company cannot make a reasonably reliable estimate of when the first commercial sales would take place.

RELATED PARTIES TRANSACTIONS

RELATED PARTIES TRANSACTIONS	9 Months Ended	12 Months Ended
	Jun. 30, 2016	Sep. 30, 2015
RELATED PARTIES TRANSACTIONS	5. RELATED PARTIES TRANSACTIONS As of June 30, 2016 and September 30, 2015, the amount due to a related party, BioLite, Inc (“BioLite”) was $0 and $22,517 respectively. As of June 30, 2016 and September 30, 2015, the amount due to shareholder, YuanGene Corporation, was $0 and $46,586 respectively.
Metu Brands, Inc [Member]
RELATED PARTIES TRANSACTIONS		Note 3 — Related Party Transactions We have borrowed funds for our operations from certain major stockholders, directors and officers as disclosed below. We have an unsecured demand note payable due of $9,000 to Shulamit Lazar, our sole officer and director for funds advanced the Company through the bankruptcy process. This is unsecured with a zero percent interest rate and is payable on demand. As part of the bankruptcy sale Shulamit Lazar was awarded all 271 of the convertible preferred shares. Shulamit Lazar received compensation of 30,000,000 shares valued at $30,000 during the year ended September 30, 2015.

ACCOUNTS PAYABLE

ACCOUNTS PAYABLE	9 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE	6. ACCOUNTS PAYABLE As of June 30, 2016 and September 30, 2015, the amount Accounts Payable to LiteArt, Inc. was $11,446 and $0 respectively.

Notes Payable

Notes Payable	9 Months Ended
	Jun. 30, 2016
Notes Payable	7. SHORT TERM LOAN The Company entered a short term agreement of $2,050,000 with Shin Kong Bank with a period of three months. The loan was guaranteed by the related party, BioLite. Pursuant to the loan agreement, the interest rate is LIBOR plus 1.5%. The loan was subsequently paid off on August 9, 2016.

SHORT TERM LOAN

SHORT TERM LOAN	9 Months Ended
	Jun. 30, 2016
Short Term Loan
SHORT TERM LOAN	7. SHORT TERM LOAN The Company entered a short term agreement of $2,050,000 with Shin Kong Bank with a period of three months. The loan was guaranteed by the related party, BioLite. Pursuant to the loan agreement, the interest rate is LIBOR plus 1.5%. The loan was subsequently paid off on August 9, 2016.

EQUTIY

EQUTIY	9 Months Ended	12 Months Ended
	Jun. 30, 2016	Sep. 30, 2015
EQUTIY	8. EQUTIY During October 2015, $350,000 of subscription receivable was fully collected from the shareholders. On February 8, 2016, a Share Exchange Agreement ("Share Exchange Agreement") was entered into by and among American BriVision (Holding) Corporation (the "Company"), American BriVision Corporation ("BriVision"), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China ("Euro-Asia"), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the "BriVision Stock"). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the "Acquisition Stock") (subject to adjustment for fractionalized shares as set forth below) of the Company's common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company's common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision's common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company's common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company's common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company's common stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the "Share Exchange"), BriVision became a wholly owned subsidiary (the "Subsidiary") of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the “Forward Stock Split”) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.
Metu Brands, Inc [Member]
EQUTIY		Note 6 — Equity Common Stock As of September 30, 2014 the Company had 11,144 common shares issued and outstanding and 90,000,000 shares of Common Stock authorized par value $0.001 and the holders of the Company's common stock are entitled to one vote per each share of common stock held. Additionally as part of the bankruptcy sale the Company has had a reverse stock split of 5,000 for 1 on August 13, 2014 which has been reflected retroactively in these financial statements. 30,000,000 shares of common stock was issued to Shulamit Lazar for her initial $20,000 deposit to purchase the company. The Company also issued 30,000,000 shares of common stock in the year ended September 30, 2015 to a related party (Shulamit Lazar) for services valued at $30,000. As of September 30, 2015 the company had 60,011,144 common shares outstanding. Preferred Stock As of September 30, 2015 the Company had 10,000,000 shares of Preferred Stock authorized par value $.001 and the holders of the Company's Preferred Stock can convert each share into 100,000 shares of voting Common Stock. Additionally each Preferred Share is entitled to the voting rights 100,000 common stock shares. Subsequent to the date of these financial statements but prior to issuance the preferred shares have been amended to carry voting and conversion rights equal to 20,000 common shares each. The Company had 271 shares issued during bankruptcy to Innovation Consulting LLC for $5,000 and 271 shares were issued and outstanding as of September 30, 2015.

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
	Jun. 30, 2016
EARNINGS PER SHARE	Note 9 - EARNINGS PER SHARE Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares and dilutive potential common shares outstanding during the period. 2015 2014 Net (Loss) $ (32,281 ) $ (23,235 ) Weighted-average common shares outstanding basic Weighted-average common stock equivalents 5,000,929 11,144 Stock options - - Warrants - - Preferred stock 27,100,000 27,100,000 Weighted-average common shares outstanding - basic and diluted 3,303,773 10,000 Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Jun. 30, 2016	Sep. 30, 2015
COMMITMENTS AND CONTINGENCIES	10. COMMITMENTS AND CONTINGENCIES Capital Commitment On December 29, 2015, the Company entered into the agreement with Biolite, a related party, that Biolite would grant the Company sole licensing rights of a series of technology for 10 years. The total consideration of obtaining such grant would be $100,000,000. As of June 30, 2016, $3,500,000 was paid to BioLite as the prepayment.
Metu Brands, Inc [Member]
COMMITMENTS AND CONTINGENCIES		Note 5 — Commitments and Contingencies Contingencies. All contingencies have been settled through our bankruptcy petition in September 2014 subsequent to this financial reporting period. Lease Commitments. None.

Stock Options

Stock Options	12 Months Ended
	Sep. 30, 2015
Metu Brands, Inc [Member]
Stock Options	Note 7 — Stock Options There were no stock options issued during the fiscal years ended September 30 2015 and 2014. As part of our bankruptcy agreement approved on September 19, 2014 all common conversion rights of any kind including the equity compensation plan without limitation , warrants, options and convertible notes were cancelled and extinguished for the current and prior fiscal years.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2015
Metu Brands, Inc [Member]
Income Taxes	Note 8 — Income Taxes As of September 30, 2015, the Company had approximately $85,516 in post bankruptcy net operating loss carry forwards for federal income tax purposes which expire between 2015 and 2033. Generally, these can be carried forward and applied against future taxable income at the tax rate applicable at that time. We are currently using a 15% effective tax rate for our projected available net operating loss carry-forward. However, as a result of potential stock offerings and stock issuance in connection with potential acquisitions, as well as the possibility of the Company not realizing its business plan objectives and having future taxable income to offset, the Company’s use of these NOLs may be limited under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended. Components of deferred tax assets and (liabilities) are as follows: 2015 2014 Net operating loss carry forwards valuation available $ 85,516 $ 23,235 Valuation Allowances (29,075 ) (3,485 ) Deferred Tax Asset 29,075 3,485 Net Deferred Tax Asset $ -0- $ -0- In accordance with FASB ASC 740 “Income Taxes”, valuation allowances are provided against deferred tax assets, if based on the weight of available evidence, some or all of the deferred tax assets may or will not be realized. The Company has evaluated its ability to realize some or all of the deferred tax assets on its balance sheet for the coming year and has established a valuation allowance in the amount of $29,075 at September 30, 2015 During the period ended September 30, 2015 the company did not utilize any of its NOL.

Acquisitions

Acquisitions	12 Months Ended
	Sep. 30, 2015
Metu Brands, Inc [Member]
Acquisitions	Note 10 - Acquisitions On September 25, 2014 the company entered into an agreement to buy the ready to operate business assets of Metu Brands Inc. The cost of this acquisition was $10,000 which was allocated $795 to inventory and $9,205 to the intangible assets of the "MeTu" trade name and web site MeTuBoutique.com.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2015
Metu Brands, Inc [Member]
Subsequent Events	Note 11 - Subsequent Events We have evaluated subsequent events and transactions that occurred through the date and time our financial statements were issued for potential recognition or disclosure in the accompanying financial statements. Other than the change in preferred shares rights itemized in note 6 above, we did not identify any events or transactions that should be recognized or disclosed in the accompanying financial statements.

SUMMARY OF SIGNIFICANT ACCOUN22

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Jun. 30, 2016	Sep. 30, 2015
Basis of Presentation	Basis of Presentation The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting. Consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company's financial statements are expressed in U.S. dollars. The condensed financial statements include all adjustments that, in the opinion of management, are necessary in order not to make the financial statements misleading. Certain information and footnote disclosure normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. The results of operations for the periods ended June 30, 2016 are not necessarily indicative of the operating results for the full year.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.
Forward Stock split	Forward Stock split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation. See Note 4 for more details.
Fair Value Measurements	Fair Value Measurements The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: • • • There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of September 30, 2015.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of June 30, 2016, the Company's cash and cash equivalents amounted $84,904. As of September 30, 2015, the Company's cash and cash equivalents amounted $994,830. All of the Company's cash deposits are held in a financial institution located in Republic of China where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality. The Company owns no legal entities in PRC.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. As of June 30, 2016 and September 30, 2015, the Company’s income tax expense amounted $836 and $0, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.
Metu Brands, Inc [Member]
Description of the Company		Description of the Company
Reclassifications		Reclassifications
Basis of Presentation		Basis of Preparation
Principles of Consolidation		Principles of Consolidation
Use of Estimates		Use of Estimates
Revenue Recognition		Revenue Recognition
Loss Per Share		Loss Per Share
Property and Equipment		Property and Equipment Computer equipment 3-10 years Furniture and fixtures 3-7 years Test equipment 5-7 years Signs 7 years Software 3 years Marketing and Promotional Video 3 years Repairs and maintenance costs are charged to operations as incurred. Betterments or renewals are capitalized as incurred.
Patents		Patents
Long-Lived Assets		Long-Lived Assets
Stock-Based Compensation		Stock-Based Compensation We account for stock options granted to non-employees under the fair-value method with stock-based compensation expense being charged to earnings on the earlier of the date services are performed or a performance commitment exists.
Recent Accounting Pronouncements		Recent Accounting Pronouncements We have reviewed all Accounting Standards Updates issued by the Financial Accounting Standards Board since we last issued financial statements and have determined none of them would have a material effect on the consolidated financial statements upon adoption.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2015
Metu Brands, Inc [Member]
Schedule of equipment useful life	Depreciation is recorded using the straight-line method over the following useful lives: Computer equipment 3-10 years Furniture and fixtures 3-7 years Test equipment 5-7 years Signs 7 years Software 3 years Marketing and Promotional Video 3 years

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2015
Metu Brands, Inc [Member]
Schedule of deferred tax assets and liabilities	Components of deferred tax assets and (liabilities) are as follows: 2015 2014 Net operating loss carry forwards valuation available $ 85,516 $ 23,235 Valuation Allowances (29,075 ) (3,485 ) Deferred Tax Asset 29,075 3,485 Net Deferred Tax Asset $ -0- $ -0-

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	12 Months Ended
	Sep. 30, 2015
Metu Brands, Inc [Member]
Schedule of reconciliation for basic and diluted EPS	The following is a reconciliation of the computation for basic and diluted EPS for the years ended September 30, 2015 and 2014: 2015 2014 Net (Loss) $ (32,281 ) $ (23,235 ) Weighted-average common shares outstanding basic Weighted-average common stock equivalents 5,000,929 11,144 Stock options - - Warrants - - Preferred stock 27,100,000 27,100,000 Weighted-average common shares outstanding - basic and diluted 3,303,773 10,000

ORGANIZATION AND DESCRIPTION 26

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) - shares	Jun. 30, 2016	Feb. 08, 2016	Sep. 30, 2015
Common stock, issued	209,352,897		166,273,921
Share Exchange Agreement [Member]
Percentage of common shares issued and outstanding		79.70%
Share Exchange Agreement [Member] | American BriVision (Holding) Corporation [Member]
Common stock, issued		52,936,583
Percentage of common shares issued and outstanding		100.00%
Share Exchange Agreement [Member] | Euro-Asia Investment & Finance Corp. Limited [Member]
Common stock, issued		51,945,225
Share Exchange Agreement [Member] | American BriVision Corporation [Member]
Common stock, issued		52,336,000

SUMMARY OF SIGNIFICANT ACCOUN27

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Metu Brands, Inc [Member]	12 Months Ended
	Sep. 30, 2015
Computer Equipment [Member] | Minimum [Member]
Property and equipment, useful lives	P3Y
Computer Equipment [Member] | Maximum [Member]
Property and equipment, useful lives	P10Y
Furniture and Fixtures [Member] | Minimum [Member]
Property and equipment, useful lives	P3Y
Furniture and Fixtures [Member] | Maximum [Member]
Property and equipment, useful lives	P7Y
Test Equipment [Member] | Minimum [Member]
Property and equipment, useful lives	P5Y
Test Equipment [Member] | Maximum [Member]
Property and equipment, useful lives	P7Y
Signs [Member]
Property and equipment, useful lives	P7Y
Software [Member]
Property and equipment, useful lives	P3Y
Marketing And Promotional Video [Member]
Property and equipment, useful lives	P3Y

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Mar. 21, 2016	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2016
Accounting Policies [Abstract]
Description of forward split	1 to 3:141
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, authorized	360,000,000	360,000,000	360,000,000	360,000,000
Cash and cash equivalents		$ 994,830	$ 84,904	$ 84,904
Income tax expense			$ 836	$ 836

COLLAOBRATIVE AGREEMENT (Detail

COLLAOBRATIVE AGREEMENT (Details Narrative) - Collaborative Agreement [Member] - BioLite Inc., [Member] - Licensing Rights For Drug And Therapeutic Use of Five Products [Member] - USD ($)	May 06, 2016	Dec. 29, 2015	Jun. 30, 2016
Total consideration	$ 2,600,000	$ 100,000,000
Upfront payment		$ 3,500,000
Value of shares issued for aquisition	$ 900,000
Number of shares issued for aquisition	562,500
Share price (in dollars per share)	$ 1.60
Description of agreement terms

RELATED PARTIES TRANSACTIONS (D

RELATED PARTIES TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2016	Dec. 02, 2015
Metu Brands, Inc [Member] | 0% Unsecured Note Due On Demand [Member] | Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares issued upon bankruptcy sale	271
BioLite, Inc [Member]
Related Party Transaction [Line Items]
Notes payable due	$ 22,517	$ 0
YuanGene Corporation [Member]
Related Party Transaction [Line Items]
Notes payable due	$ 46,586	$ 0
Mr.Shulamit Lazar [Member] | Metu Brands, Inc [Member]
Related Party Transaction [Line Items]
Number of shares issued upon services rendered	30,000,000
Value of shares issued upon services rendered	$ 30,000
Mr.Shulamit Lazar [Member] | Metu Brands, Inc [Member] | 0% Unsecured Note Due On Demand [Member]
Related Party Transaction [Line Items]
Notes payable due	$ 9,000
Notes payable cancelled			$ 9,000

ACCOUNTS PAYABLE (Details Narra

ACCOUNTS PAYABLE (Details Narrative) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Accounts payable	$ 11,446
LiteArt, Inc. [Member]
Accounts payable	$ 11,446	$ 0

EQUTIY (Details Narrative)

EQUTIY (Details Narrative) - USD ($)	Mar. 21, 2016	Aug. 13, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2016	Oct. 31, 2015
Common stock, issued			166,273,921		209,352,897
Common stock, outstanding			166,273,921		209,352,897
Common stock, authorized	360,000,000		360,000,000		360,000,000
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001		$ 0.001
Description of forward split	1 to 3:141
Subscription receivable			$ 350,000			$ 350,000
Metu Brands, Inc [Member]
Common stock, issued			60,011,144	11,144
Common stock, outstanding			60,011,144	11,144
Common stock, authorized			90,000,000	90,000,000
Common stock, par value (in dollars per share)			$ 0.001	$ 0.001
Description common sharesholders voting rights				Entitled to one vote per each share of common stock held.
Description of forward split		5,000 for 1
Subscription receivable			$ 350,000
Metu Brands, Inc [Member] | Convertible Preferred Stock [Member]
Preferred stock, authorized			10,000,000
Preferred stock, par value (in dollars per share)			$ 0.001
Each preferred shares converted into voting common stock			100,000
Description preferred sharesholders voting rights			Each Preferred Share is entitled to the voting rights 100,000 common stock shares.
Preferred stock, issued			271
Preferred stock, outstanding			271
Metu Brands, Inc [Member] | Convertible Preferred Stock [Member] | Subsequent Event [Member]
Each preferred shares converted into voting common stock			20,000
Metu Brands, Inc [Member] | Mr.Shulamit Lazar [Member]
Number of shares issued upon initial deposit			30,000,000
Intial deposit			$ 20,000
Number of shares issued upon services rendered			30,000,000
Value of shares issued upon services rendered			$ 30,000
Metu Brands, Inc [Member] | Innovation Consulting LLC [Member] | Convertible Preferred Stock [Member]
Number of shares issued upon bankruptcy sale			271
Number of shares issued upon conversion			5,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - BioLite, Inc [Member]	Dec. 29, 2015USD ($)
Loss Contingencies [Line Items]
Total consideration	$ 100,000,000
Agreement period	15 years

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - Metu Brands, Inc [Member]	12 Months Ended
	Sep. 30, 2015USD ($)
Post bankruptcy operating loss carryforward	$ 85,516
Description of operating loss expiration period	Expire between 2015 and 2033
Current effective tax rate	15.00%

Income Taxes (Details)

Income Taxes (Details) - Metu Brands, Inc [Member] - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Net operating loss carry forwards valuation available	$ 85,516	$ 23,235
Valuation Allowances	(29,075)	(3,485)
Deferred Tax Asset	29,075	3,485
Net Deferred Tax Asset	$ 0	$ 0

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - Metu Brands, Inc [Member]	Sep. 25, 2014USD ($)
Purchase price	$ 10,000
Purchase price allocated to inventory	795
Purchase price allocated to intangible assets ("MeTu" trade name and web site MeTuBoutique.com)	$ 9,205

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Sep. 30, 2014	Sep. 18, 2014
Net Income (loss)	$ (23,235)	$ (315,602)	$ (293,237)	$ (353,605)	$ (32,281)		$ (70)
Weighted-average common shares outstanding basic
Weighted-average common shares outstanding- basic and diluted (in shares)		160,823,831	208,845,898	188,626,862
Metu Brands, Inc [Member]
Net Income (loss)		$ (315,602)			$ (32,281)	$ (23,235)
Weighted-average common shares outstanding basic
Weighted-average common stock (in shares)					5,000,929	11,144
Stock options exercised					$ 0	$ 0
Preferred stock					$ 27,100,000	$ 27,100,000
Weighted-average common shares outstanding- basic and diluted (in shares)		160,823,831			5,000,929	10,000